Ten years of pediatric experience with ciprofloxacin

Infectious Diseases in Clinical Practice

Volumn 7, Issue 3, 1998, Pages S175-S183

  Rigden Green, Stephen D ^a  

^a ST LUKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ANTIBIOTIC THERAPY; ARTHROPATHY; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; ENTEROPATHY; EXPERIENCE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; OSTEOMYELITIS; OTITIS MEDIA; PEDIATRICS; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; TOPICAL DRUG ADMINISTRATION; URINARY TRACT INFECTION;

EID: 0031694318     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/00019048-199809000-00011     Document Type: Article

References (84)

1. Schaacl UB, abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995;14:1-9
2. Panel discussion. Pediatr Infect Dis J 1997; l6C.suppl: 160-2
3. Ingham B, Brentnall DW, Dale EA, et al. Arthropathy induced by antibacterial fused 7V-alkyl-4-pyridone-3-carboxylic acid. Toxicol Lett 1977;1:21-6
4. Burkhardt JE, ITill MA, Carlton WW, et al. Histologic and bistochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 1990;27:162-70
5. Burkhardt JE, Hill MA, Carlton WW, Morphologic and biochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin. Toxicol Pathol 1992; 20:246-52
6. Kato M, OnoderaT. Morphologic investigations of cavity formation in articular cartilage lesions induced by ofloxacin in rats. Fundam Appl Toxicol 1988;11:110-9
7. Tatsumi H, Senda IT, Yatera S, et al. Toxicological studies on pipemidic acid: effect on cliaithrodial joints of experimental animals. Toxol Sci 1978;3:357-67
8. Stahlmann R, Merker HJ, Hinz N, et al. Ofloxacin in juvenile non-human primates and rats: arthropathia and drug plasma concentrations. Arch Toxicol 1990;64:193-204
9. Stahlmann R, Forster C, van Sickle D. Quinolones in children: are concerns over arthropathy justified? Drug Saf 1993;9:397-403
10. Machida M, Kusajima H, Aijima H, et al, Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. Toxicol Appl Pharmacol 1990;105:403-12
11. Meissner A, Borner K, Koeppe P. Concentrations of ofloxacin in human bone and cartilage. J Antimicrob Chemother 1992;26(suppl D):69-74
12. Yulish BS, Lieberman JM, Newman AJ, et al. Juvenile rheumatoid arthritis: assessment with MR imaging. Radiology 1987;165:149-52
13. Schleuter G. Ciprofloxacin: toxicologic evaluation of additional safety data. AmJ Med 1989;87(5A suppl):37-9
14. Kubin R. Safety and efficacy of ciprofloxacin in pediatric patients [Review], Infection 1993;21:413-21
15. Hampel B, Hullman MS, Schmidt AD. Ciprofloxacin in pediatrics: a worldwide clinical experience based on compassionate use: safety reports. Pediatr Infect Dis J 1997;16:127-9
16. Jick S. Ciprofloxacin safety in a pediatric population, Pediatr Infect Dis J 1997;16:130-4
17. Rubio TT, Miles MV, Lettieri JT, et al. Clinical and laboratory experience with ciprofloxacin in children two to sixteen years of age. Pediatr Infect Dis J 1997;16:112-7
18. Schaad UB, Wedgewood J, Ruedeberg A, et al. Ciprofloxacin as antipseuclomonal treatment in patients with cystic fibrosis. Pediatr Infect Dis J 1997;16:106-11
19. Church DA, Jamshed FK, Kuhn RJ, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr Infect Dis J 1997;16:97-105
20. Richard DA, Nousia-Arvanitakis S, Sollich V, et al. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997; 16:572-8
21. Pradhan KM, Arora NK, Jena A, et al. Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta Pae-diatr 1995;84:555-60
22. Karande S, Kshirasagar NA, Ciprofloxacin use: acute arthropathy and long-term follow up. Indian Pediatr 1996;33:910-6
23. Bethell DB, Hien TT, Phi LT, et al. Effects on growth of single short courses of fluoroquinolones, Arch Dis Child 1996;74:44-6
24. Green SDR, Tlllotson G. Use of ciprofloxacin in developing countries. Pediatr Infect Dis J 1997;16:150-9
25. Salam MA, Khan WA, Dhar U, et al. Randomised, double blinded comparison of ciprofloxacin suspension and pi-vamdinocillin tablets in the treatment of shigellosis in children [Abstract LM-17]. Clinical Trials of Antimicrobials and Unique Instructive Clinical Observations. 1997
26. Danisovicova A, Brezina M, Belan S, et al. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy: a multicenter survey. Chemotherapy 1994;40:209-14
27. Koch C, Lanng S. Arthropathy, arthritis and vasculitis. In: Hodson ME, Geddes DM, editors. Cystic fibrosis. London: Chapman and Hall; 1995. p. 306-7
28. Schidlow DV, Goldsmith DP, Palmer J, et al, Arthritis in cystic fibrosis. Arch Dis Child 1984;59:377-9
29. Longfield R. Nontyphoidal salmonella infections, In: Strickland GT, editor. Hunter’s Tropical Medicine. 7th ed, Philadelphia: WB Saunders; 1991. p. 364
30. Chysky V, Kapila K, Hullman R, et al. Quinolones in clinical use: safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use-emphasis on joint evaluation. Infection 1991;19:289-96
31. Aujard Y. Quinolones in neonates. Aclv Antimicrob Anti-neoplast Chemother 1992;11-2(suppl):S233-S237
32. Green SDR, Ilunga F, Cheesbrough JS, et al. The treatment of neonatal meningitis due to gram negative bacilli with ciprofloxacin: evidence of satisfactory penetration into cerebrospinal fluid. J Infect 1993;26:253-6
33. Bhutta ZA, Farooqui BJ, Sterm AW. Eradication of a multiple resistant Salmonella paratyphi A causing meningitis with ciprofloxacin. J Infect 1992;25:215-9
34. Rangunathan PL, Potkins DV, Watson JG, et al. Neonatal meningitis due to Salmonella typhimurium treated with ciprofloxacin. J Antimicrob Chemother 1990;26: 727-8
35. Isaacs D, Slack PME, Wilkinson AR, et al. Successful treatment of Pseudomonas ventriculitis with ciprofloxacin. J Antimicrob Chemother 1986;17:5335-8
36. Hansen LN, Eschen C, Bruun B. Neonatal salmonella meningitis: two case reports. Acta Paediatr 1996;85:629-31
37. Green SDR, Ilunga FM, Numbi A, et al, An open study of ciprofloxacin for the treatment of proven or suspected extraintestinal salmonellosis in African children: a preliminary report. Adv Antimicrob Antineoplast Chemother 1992;11-2(suppl D):S181-S187
38. Orenstein DM, Pattishal EN, Noyea BE, et al. Safety of ciprofloxacin in children with cystic fibrosis. Clin Pediatr 1993;32:504-6
39. Nuutinen M, Turtinen J, Uhari M. Growth and joint symptoms in children treated with nalidixic acid, Pediatr Infect Dis J 1994;13:798-800
40. Schaad UB, Wedgewood-Kruko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 1987;15:165-8
41. Chevalier X, Albengres E, Voisin MC, et al. A case of destructive polyarthropathy in a 17-year-old youth following pefloxacin treatment. Drug Saf 1992;7:310-4
42. Ribard P, Audisio F, Kahn MF, et al. Seven achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy. J Rheumatol 1992;19:1479-81
43. Perrot S, Ziza JM, De Bourran-Cauet G, et al, Nouvelle complication liée aux quinolones: la rupture du tendon Achille, Presse Med 1991;20:1234
44. Pertuiset E, Lenoir G, Jehanne M, et al. Tolerance articulaire de la pefloxacine et de l’ofloxacine chez les enfants et adolescents atteints de mucoviscidose. Rev Rhum Mal Osteoartic 1989;56:735-40
45. Miller MS, Gaiclo E, Rourk MIT, et al. Anaphylactoid reactions to ciprofloxacin in cystic fibrosis patients. Pediatr Infect Dis J 1991;10:164-5
46. Wurtz RM, Abrams D, Becker S, et al. Anaphylactoid drug reactions to ciprofloxacin and rifampicin in ITIV-infected patients. Lancet 1989;1:955-6
47. Simpson J, Watson AR, Mellersh A, et al. Typhoid fever, ciprofloxacin and renal failure. Arch Dis Child 1991; 66:1083-4
48. Winrow AP, Supramaniam G. Benign intracranial hypertension after ciprofloxacin administration. Arch Dis Child 1990;65:1165-6
49. Rosolen A, Drigo P, Zanesco L. Acute hemiparesis associated with ciprofloxacin. BMJ 1994;309:14ll
50. Singh J, Agarwal AK, Sudrania SP. Extrapyramidal syndrome following ciprofloxacin treatment. Indian Pediatr 1994;31:608-9
51. Rfidah EI, Findlay CA, Beattie TJ. Reversible encephalopathy after intravenous ciprofloxacin therapy. Pediatr Nephrol 1995;9:250-1
52. Dey SK. Nightmare due to ciprofloxacin in young patients. Indian Pediatr 1995;32:918-9
53. Win A, Evers ML, Chmel H. Stevens-Johnson syndrome presumably induced by ciprofloxacin. Int J Dermatol 1994;33:512-4
54. Hascimustafaoglu M, Cil E, Nacarkupuk E. Unusual adverse effects of ciprofloxacin: purpuric reactions and local venospasm. Pediatr Infect Dis J 1995;6:551-2
55. Lumbiganon P, Pengsaa K, Sookpranee T. Ciprofloxacin in neonates and its possible adverse effects on the teeth. Pediatr Infect Dis J 1991;10:619-20
56. Gardner DK, Gabbe SG, Harter C. Simultaneous concentrations of ciprofloxacin in breast milk and serum in mother and breast-fed infant. Clin Pharmacol 1992;11: 352-4
57. Harmon T, Burkhart G, Applebaum PI. Perforated pseudomembranous colitis in the breast-fed infant. J Pae-diatr Surg 1992;27:744-6
58. Peltola I-I, Vaarala M, Renkonen OV, et al. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob Agents Chemother 1992;36: 1086-90
59. Bergogne-Berezin E. Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree. Infection 1987;15:288-94
60. Davis R, Koup J, Williams-Warren J, et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 1987;35:915-9
61. Reed M, Stern R, Myers C, et al. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. J Clin Pharmacol 1988;28:691-9
62. I-Ioiby N. Microbiology of lung infections in cystic fibrosis patients. Acta Pediatr Scand Suppl 1982;301:33-54
63. Regelmann WE, Elliott GR, Warwick WJ, et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-21
64. Diver JM, Schollaardt T, Rabin PIR, et al. Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother 1991;35:1538-46
65. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonisation with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5
66. St. Geme J, Plodes HL, Marcy SM, et al. Consensus management of salmonella infection in the first year of life. Pediatr Infect Dis J 1988;7:615-21
67. Maiorini E, Lopez EL, Morrow AL, et al. Multiply resistant nontyphoidal salmonella gastroenteritis in children. Pe-diatr Infect Dis J 1993;12:139-44
68. Lepage P, Bogaerts J, Van Goethem C, et al. Community-acquired bacteraemia in African children. Lancet 1987; 1:1458-61
69. Green SDR, Cheesbrough J. Salmonella bacteraemia among young children at a rural hospital in Western Zaire. Ann Trop Paediatr 1993;13:45-54
70. Bavdekar A, Chaudhari M, Bhave S, et al. Ciprofloxacin in typhoid fever. Indian J Pediatr 1991;58:335-9
71. Sen S, Goyal RS, Dev R. Ciprofloxacin in the management of multiple drug resistant typhoid fever. Indian Pediatr 1991;28:417-9
72. Arora RK, Gupta A, Joshi NM, et al. Multidrug resistant typhoid fever: study of an outbreak in Calcutta. Indian Pediatr 1992;29:61-6
73. Dutta P, Rasaily R, Saha MR. Ciprofloxacin for the treatment of severe typhoid fever in children. Aclv Antimicrob Antineoplast Chemother 1993;37:1197-9
74. Bennish ML, Harris JR, Wojtyniak BJ, et al. Death in shigellosis: incidence and risk factors in hospitalised patients. J Infect Dis 1990;161:500-6
75. Bennish ML, Salam MA, Khan WA, et al. Treatment of shigellosis. III. Comparisons of one or two dose ciprofloxacin with standard five day therapy, Ann Intern Med 1992;177:727-34
76. Khan WA, Sears S, Khan EH, et al. Randomised double blinded comparison of single dose ciprofloxacin with single dose cloxycycline in the treatment of Vibrio cbolerae 0139 (Bengal) infection [Abstract, M51]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994; Orlando (FL). Washington (DC): American Society for Microbiology, 1994
77. Van Wijk JEA, De Jong TPVM, Van Gool JD, et al. Using quinolones in urinary tract infections in children. Aclv Antimicrob Antineoplast Chemother 1992; 11-12(suppl): 157-61
78. Lotti T, Mirone V, Imbimbo C, et al. Ciprofloxacin in the treatment of urinary tract infections. J Int Mecl Res 1987;15:240-4
79. Martorana G, Gilberti C, Pizzorno R, et al. Treatment of urinary tract infections with ciprofloxacin. Clin Ther 1988;10:516-20
80. Lang R, Goshen S, Raas-Rothschild A. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: preliminary experiences in 21 children. Pediatr Infect Dis J 1992;11:925-9
81. Force RW, Hart MC, Plummer SA, et al. Topical ciprofloxacin for otorrhea after tympanostomy tube placement. Arch Otolarngol Head Neck Surg 1995; 121: 880-4
82. Tsui H-F, Chiu K-H, Leung K-S. Osteomyelitis of the spine due to salmonella infection: conservative treatment with quinolone: a case report. Can J Surg 1997;40:48-50
83. Bergan T. Extravascular penetration of ciprofloxacin: a review. Diagn Microbiol Infect Dis 1990;13:103-14
84. Cuevas LE, Kazembe P, Mughogho GK, et al. Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin. J Infect Dis 1995;171:728-31